# US 2021/0174900 A1 · Methods for Introducing Mutations That Alter the Probability of Intranucleic Acid Base Pairing of a Conserved Structured Nucleotide and Related Compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0174900 A1
- Document ID: US20210174900A1
- Status: Published application
- Kind: A1
- Application number: 17/075,690
- Filed: 2020-10-20
- Published: 2021-06-10
- Earliest claimed: 2014-02-27
- Assignees: CureLab, Inc.
- Applicants: CureLab, Inc.
- Inventors: Andrey Chursov; Alexander Shneider
- Web page: https://patentgrep.com/patent/US20210174900A1

## CPC

- G16B 30/00: ICT specially adapted for sequence analysis involving nucleotides or amino acids
- A61K 39/145: Orthomyxoviridae, e.g. influenza virus
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- G06F 17/18: for evaluating statistical data {, e.g. average values, frequency distributions, probability functions, regression analysis (forecasting specially adapted for a specific administrative, business or logistic context G06Q10/04)}
- G16B 20/00: ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
- G16B 20/20: Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
- G16B 20/50: Mutagenesis
- G16B 30/10: Sequence alignment; Homology search
- A61K 2039/5254: {avirulent or attenuated}
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G06F: ELECTRIC DIGITAL DATA PROCESSING (computer systems based on specific computational models G06N)

## Abstract

The present invention relates generally to methods for introducing mutations that alter the probability of intranucleic acid base pairing of a conserved structured nucleotide in a nucleic acid. The present invention also provide methods for making mutant pathogenic organisms suitable as live attenuated vaccines, animal and human diagnostics, and for identifying suitable drug targets.

## Claims

### Claim 1

A method of introducing a mutation into a nucleic acid that alters the probability of intranucleic acid base pairing of a conserved structured nucleotide comprising:
a) introduction of a mutation at an identity conserved nucleotide position i, 0<i<L;+1, wherein L; is the length of the nucleic acid sequence, in the nucleotide sequence corresponding to said nucleic acid;
b) determination of the probability of intranucleic acid base pairing for a structure conserved nucleotide position j, 0<j<Lj+1, in said nucleic acid sequence in the presence of the mutation (Pm);
c) comparison of Pm to a threshold probability of intranucleic acid base pairing for a structure conserved nucleotide position j in said nucleic acid sequence comprising;
i) Comparison of Pm to Pmin wherein Pmin is a minimum threshold probability of intranucleic acid base pairing for a structure conserved nucleotide position j in said nucleic acid sequence; or,
ii) Comparison of Pm to Pmax wherein PmaX is a maximum threshold probability of intranucleic acid base pairing for a structure conserved nucleotide position j in said nucleic acid sequence; wherein if Pm<Pmm or Pm>Pmax said mutation is identified as a structure conserved altering mutation; and,
d) introduction of said mutation into said nucleic acid when said mutation is a structure conserved altering mutation.

### Claim 2 (depends on 1)

The method of claim 1, wherein said identity conserved position i is determined by a method comprising:
a) determination of the probability of a nucleobase occurring at a nucleotide position for each nucleobase, wherein p(A); p(U) p(C) p(G); is the probability of adenine, uracil, cytosine or guanine nucleobase occurring at said nucleotide position, respectively;
b) determination of the position-specific mutability M; at said nucleotide position according to the formula:
Mi=−p(A)i*log 2(p(A)−p(C);*log 2(p(C);)−p(G);*log 2(p(G);)−p(U);*log 2(p(U);)
c) comparison of Mi to Mmx, wherein Mmx is a maximum threshold mutability; and, d) determination of said nucleotide position as an identity conserved position when M; <Mmx.

### Claim 3 (depends on 2)

The method of claim 2, wherein said probability of a nucleobase occurring at a nucleotide position is determined by the method comprising:
a) determination of the frequency of a nucleobase at a nucleotide position C(B)i among N native variant sequences,
b) wherein B is an adenine, uracil, cytosine or guanine nucleobase; and,
c) determination of said probability of a nucleobase occurring at a nucleotide position by the equation p(B); =(C(B+1)/(N+4).

### Claim 4 (depends on 1)

The method of claim 1, wherein Pmax is determined by a method comprising:
a) For a nucleotide position i, 0<i<L+1, where L is the length of said alignment of said native variants of said nucleic acid sequences, determine the mean value of said position-specific set of probabilities.
b) For a nucleotide position i, 0<i<L+1, determine said position-specific range of allowed probabilities as the range from said mean value of said position-specific set of probabilities decreased by said standard deviation of said position-specific set of probabilities multiplied by K, to said mean value of said position-specific set of probabilities increased by said standard deviation of said position-specific set of probabilities multiplied by K.

### Claim 5 (depends on 2)

The method of claim 2, wherein said Mmax is determined by a method comprising:
a) determine mutability values for all nucleotide positions i; and,
b) designate Mmax at a percentile of all mutability values.

### Claim 6 (depends on 5)

The method of claim 5, wherein said percentile is selected from the group consisting of: 1, 2, 2.5, 5, 10, 15, 20, 25, 30, 35, 40, and 50.

### Claim 7 (depends on 1)

The method of claim 1, wherein said structure conserved nucleotide position j is determined by a method comprising:
a) alignment of N native variant nucleic acid sequences of said nucleic acid where L is the length of the aligned native variant nucleic acid sequences;
b) determination of the probability of intranucleic acid pairing for a nucleotide at position j for each aligned native variant nucleic acid sequence to obtain a plurality of probabilities of intranucleic acid pairing for a nucleotide at position j;
c) determination of the variation (V,) of said probabilities for said nucleotide at position j; and, d) comparison of Vj to Vmax, wherein Vmax is a maximum threshold variation of probability; and,
e) Determination of said nucleotide position j as a structure conserved nucleotide position when
Claim Vj<Vmax.

### Claim 8 (depends on 7)

The method of claim 7, wherein said variation is selected from the group consisting of: standard deviation, standard error and variance.

### Claim 9 (depends on 7)

The method of claim 7, wherein Vmax is determined by a method comprising:
a) For a nucleotide position i, 0<i<L+1, said standard deviation of said position-specific set of probabilities is included into a general set of standard deviations.
b) The mean value and the standard deviation of the values in said general set of standard deviations are calculated. These are the mean standard deviation and the standard deviation of standard deviations.
c) Said cutoff value is identified as said standard deviation of standard deviations multiplied by a rational non-negative number and subtracted from said mean standard deviation.

### Claim 10 (depends on 1)

The method of claim 1, wherein said nucleic acid sequence corresponds to mRNA.

### Claim 11 (depends on 7)

The method of claim 7, wherein N is at least 3.

### Claim 12 (depends on 7)

The method of claim 7, wherein said native variant nucleic acid sequences are non-redundant.

### Claim 13 (depends on 7)

The method of claim 7, wherein said native variant nucleic acid sequences have identical length.

### Claim 14 (depends on 1)

The method of claim 1, wherein said mutation is silent.

### Claim 15 (depends on 1)

The method of claim 1, wherein said nucleic acid comprises a gene from a pathogenic organism.

### Claim 16 (depends on 18)

The method of claim 18, wherein said pathogenic organism is selected from the group consisting of: Torque Teno virus (Transfusion transmitted virus), Ippy virus, Lassa fever virus, Lujo virus, Lymphocytic (strains), Lymphocytic choriomeningitis virus (other strains), Mobala virus, Mopeia virus, Amapari virus, Flexal virus, Guanarito virus, Junin virus, Latino virus, Machupo virus, Parana virus, Pichinde virus, Sabia virus, Tamiami virus, Whitewater Arroyo virus, Borna disease virus, Akabane virus, Bhanja virus, Bunyamwera virus, California encephalitis virus, Germiston virus, Oropouche virus, Belgrade (Dobrava) virus, Hantaan virus (Korean haemorrhagic fever), Puumala virus, Prospect Hill virus, Seoul virus, Sin Nombre virus (formerly Muerto Canyon), Crimean/Congo haemorrhagic fever virus, Hazara virus, Rift valley fever virus, Sandfly fever virus, Toscana virus, Norovirus (formerly Norwalk virus), Sapo virus, 29E virus, OC43 virus, SARS virus, Ebola Cote d'Ivoire virus, Ebola Reston virus, Ebola Sudan virus, Ebola Zaire virus, Marburg virus, Absettarov virus, Central European tick-borne encephalitis virus, Dengue viruses types 1-4, GB virus C (Hepatitis G virus), Hanzalova virus, Hepatitis C virus, Hypr virus, Israel turkey meningitis virus, Japanese encephalitis virus, Kumlinge virus, Kyasanur forest disease virus, Louping ill virus, Murray Valley encephalitis virus, Negishi virus, Omsk haemorrhagic fever virus, Powassan virus, Rocio virus, Russian spring summer encephalitis virus, Sal Vieja virus, San Perlita virus, Spondweni virus, St Louis encephalitis virus, Tick-borne encephalitis virus, Wesselsbron virus, West Nile fever virus, Yellow fever virus, Hepatitis B virus, Hepatitis D virus (delta), Cytomegalovirus, Epstein-Barr virus, Herpesvirus simiae (B virus), Herpes simplex virus types 1 and 2, Human herpesvirus type 6—HHV6, Human herpesvirus type 7—HHV7, Human herpesvirus type 8—HHV8 (Kaposi's sarcoma-associated herpesvirus), Varicella-zoster virus, Dhori virus, Influenza virus types A, B and C, Thogoto virus, BK virus, JC virus, KI virus, Simian virus 40 (SV40), WU virus, Human papillomaviruses, Hendra virus (formerly equine morbillivirus), Human metapneumo virus, Measles virus, Mumps virus, Newcastle disease virus, Nipah virus, Parainfluenza virus (Types 1 to 4), Respiratory syncytial virus (human), Bocavirus genus, Parvovirus B19, Human partetravirus (Parv4/Parv5), Acute haemorrhagic conjunctivitis virus (AHC), Coxsackieviruses, Echoviruses, Hepatitis A virus (human enterovirus type 72), Polioviruses, Rhinoviruses, Molluscum contagiosum virus, Buffalopox virus, Cowpox virus, Elephantpox virus, Monkeypox virus, Rabbitpox virus, Vaccinia virus, Variola virus (major and minor), Whitepox virus, Orf virus, Pseudocowpox virus (Milker's nodes virus), Tana virus, Yaba virus, Coltivirus, Human rotaviruses, Orbiviruses, Reoviruses, Human immunodeficiency viruses, Human T-cell lymphotropic viruses (HTLV) types 1 and 2, Simian immunodeficiency virus, Xenotropic murine leukemia virus-related virus, Australian bat lyssavirus, Duvenhage virus, European bat lyssaviruses 1 and 2, Lagos bat virus, Mokola virus, Piry virus, Rabies virus, Vesicular stomatitis virus, Bebaru virus, Chikungunya virus, Eastern equine encephalitis virus, Everglades virus, Getah virus, Mayaro virus, Middleburg virus, Mucambo virus, Ndumu virus, O'nyong-nyong virus, Ross river virus, Sagiyama virus, Semliki forest virus, Sindbis virus, Tonate virus, Venezuelan equine encephalitis virus, Western equine encephalitis virus, Rubella virus, Berne virus, Breda virus, Porcine torovirus, Hepatitis E virus, Actinobacillus actinomycetemcomitans, Actinomadura madurae, Actinomadura pelletieri, Actinomyces gerencseriae, Actinomyces israelii, Actinomyces spp, Alcaligenes spp, Bacillus anthracis, Bacillus cereus, Bacteroides fragilis, Bacteroides spp, Bartonella bacilliformis, Bartonella quintana, Bartonella spp, Bordetella bronchiseptica, Bordetella parapertussis, Bordetella pertussis, Bordetella spp, Borrelia burgdorferi, Borrelia duttonii, Borrelia recurrentis, Borrelia spp, Brachyspira spp (formerly Serpulina spp), Brucella abortus, Brucella canis, Brucella melitensis, Brucella suis, Burkholderia cepacia, Burkholderia mallei (formerly Pseudomonas mallei), Burkholderia pseudomallei (formerly Pseudomonas pseudomallei), Campylobacter fetus, Campylobacter jejuni, Campylobacter spp, Cardiobacterium hominis, Chlamydia trachomatis, Chlamydophila pneumoniae, Chlamydophila psittaci, Clostridium botulinum, Clostridium perfringens, Clostridium tetani, Clostridium spp, Corynebacterium diphtheriae, Corynebacterium haemolyticum, Corynebacterium pseudotuberculosis, Corynebacterium pyogenes, Corynebacterium ulcerans, Corynebacterium spp, Coxiella burnetii, Edwardsiella tarda, Ehrlichia sennetsu (Rickettsia sennetsu), Ehrlichia spp, Eikenella corrodens, Enterobacter aerogenes/cloacae, Elizabethkingia meningoseptica (formerly Flavobacterium meningosepticum), Enterobacter spp, Enterococcus spp, Erysipelothrix rhusiopathiae, Escherichia coli, verocytotoxigenic strains (eg 0157:H7 or O103), Francisella tularensis (Type A), Francisella tularensis (Type B), Fusobacterium necrophorum, Fusobacterium spp, Gardnerella vaginalis, Haemophilus ducreyi, Haemophilus influenzae, Haemophilus spp, Helicobacter pylori, Klebsiella oxytoca, Klebsiella pneumoniae, Klebsiella spp, Legionella pneumophila, Legionella spp, Leptospira interrogans (all serovars), Listeria ivanovii, Listeria monocytogenes, Moraxella catarrhalis, Morganella morganii, Mycobacterium africanum, Mycobacterium avium/intracellulare, Mycobacterium bovis, Mycobacterium chelonae, Mycobacterium fortuitum, Mycobacterium kansasii, Mycobacterium leprae, Mycobacterium malmoense, Mycobacterium marinum, Mycobacterium microti, Mycobacterium paratuberculosis, Mycobacterium scrofulaceum, Mycobacterium simiae, Mycobacterium szulgai, Mycobacterium tuberculosis, Mycobacterium ulcerans, Mycobacterium xenopi, Mycoplasma caviae, Mycoplasma hominis, Mycoplasma pneumoniae, Neisseria gonorrhoeae, Neisseria meningitidis, Nocardia asteroides, Nocardia brasiliensis, Nocardia farcinica, Nocardia nova, Nocardia otitidiscaviarum, Pasteurella multocida, Pasteurella spp, Peptostreptococcus anaerobius, Peptostreptococcus spp, Plesiomonas shigelloides, Porphyromonas spp, Prevotella spp, Proteus mirabilis, Proteus penneri, Proteus vulgaris, Providencia alcalifaciens, Providencia rettgeri, Providencia spp, Pseudallescheria boydii, Pseudomonas aeruginosa, Rhodococcus equi, Rickettsia akari, Rickettsia Canada, Rickettsia conorii, Rickettsia montana, Rickettsia prowazekii, Rickettsia rickettsii, Rickettsia tsutsugamushi, Rickettsia typhi (Rickettsia mooseri), Rickettsia spp, Salmonella arizonae, Salmonella enterica serovar enteritidis, Salmonella enterica serovar typhimurium 2, Salmonella paratyphi A, Salmonella paratyphi B/java, Salmonella paratyphi CI choleraesuis, Salmonella typhi, Salmonella spp, Shigella boydii, Shigella dysenteriae, Shigella flexneri, Shigella sonnei, Staphylococcus aureus, Streptobacillus moniliformis, Streptococcus agalactiae, Streptococcus dysgalactiae equisimilis, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus suis, Streptococcus spp, Treponema carateum, Treponema pallidum, Treponema pertenue, Treponema spp, Ureaplasma parvum, Ureaplasma urealyticum, Vibrio cholerae (including El Tor), Vibrio parahaemolyticus, Vibrio spp, Yersinia enterocolitica, Yersinia pestis, Yersinia pseudotuberculosis, and Yersinia spp

### Claim 17 (depends on 15, 16)

A method for producing a pathogenic organism lacking pathogenicity comprising:
a) Determining a mutation according to the methods of claim 15 or 16 in a gene from a pathogenic organism; and,
b) Generating a mutant pathogenic organism by introducing said mutation into said pathogenic organism, wherein said mutant pathogenic organism is non-pathogenic.

### Claim 18 (depends on 17)

A live attenuated vaccine comprising a pathogenic organism lacking pathogenicity according to claim 17 in a pharmaceutically acceptable preparation.

### Claim 19 (depends on 18)

The live attenuated vaccine according to claim 18 further comprising an adjuvant.

### Claim 20 (depends on 19)

The live attenuated vaccine according to claim 19, wherein said adjuvant is selected from the group consisting of: gel-type, microbial, particulate, oil-emulsion, surfactant-based, and synthetic adjuvant.

### Claim 21 (depends on 18)

The live attenuated vaccine according to claim 18, further comprising one or more co-stimulatory components.

### Claim 22 (depends on 21)

The live attenuated vaccine according to claim 21, wherein said one or more co-stimulatory components is selected from the group consisting of: a cell surface protein, a cytokine, a chemokine, and a signaling molecule.

### Claim 23 (depends on 18)

The live attenuated vaccine according to claim 18, further comprising one or more molecules that block suppressive or negative regulatory immune mechanisms.

### Claim 24 (depends on 23)

The live attenuated vaccine according to claim 23, wherein said one or more molecules that block suppressive or negative regulatory immune mechanisms is selected from the group consisting of: anti-CTLA-4 antibody, anti-CD25 antibody, anti-CD4 antibody, and IL13Ra2-Fc.

### Claim 25 (depends on 1)

The method of claim 1, wherein said nucleic acid is a gene from a subject and said gene is related to a disease or pathogenesis.

### Claim 26

A method of identifying human and/or animal mutations which may cause a disease comprising: a) Identification of structured RNA regions for a functionally important gene involved into disease prevention and/or pathogenesis. b) Testing a mutation for its ability to disrupt one or more structured RNA regions of the nucleic acid sequence of said gene.

### Claim 27 (depends on 25)

Method of utilizing said mutation identified according to the claim 25 for diagnostic purposes.

### Claim 28 (depends on 25)

Method of utilizing said mutation identified according to the claim 25 as drug targets.
